DNER and type 2 diabetes mellitus: Unfortunately, treatment with the bromodomain 2 (BD2)‐specific BET inhibitor apabetalone showed no significant difference in major adverse CV events (CV death, stroke and myocardial infarction) in T2DM patients with recent acute coronary syndromes and low HDL‐c compared with placebo [97].